Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Stock Report

| More

Astrazeneca receives Marketing Permission for Olaparib Tablet for treatment of Ovarian and Breast Cancer in India

Posted On: 2018-08-16 21:24:50

AstraZeneca Pharma India Limited (AZPIL) today announced that it has received Import & Market permission for olaparib (Lynparza®)100 mg and 150 mg tablets in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of olaparib (Lynparza®) in India, subject to the receipt of further related statutory approvals and licenses.

For ovarian cancer, olaparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. It is also indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

For breast cancer, olaparib is indicated for patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment Olaparib (Lynparza®) is a patented product of the AstraZeneca group.

Gagan Singh, Managing Director, AstraZeneca Pharma India Limited said, "The import and market permission for olaparib is a significant milestone for women in India living with platinum-sensitive relapsed ovarian cancer and BRCA-mutated HER-2 negative metastatic breast cancer, which has historically been difficulty-to-treat diseases. Today's approval will bring this innovative, targeted option that may help to delay disease progression for these patients."

Breast and ovarian cancers are the leading causes of cancer-related deaths in women of India. As per three-year report of population based cancer registries-2012-2014 in India, ovarian cancer is the third leading site of cancer among women, trailing behind breast and cervical cancer. The age-adjusted incidence rates of ovarian cancer vary between 1.7 and 15.2 per 100,000 population in different parts of the country [1]. Ovarian cancer has the worst prognosis among all gynaecological malignancies. The overall 5-year survival rate was 46% in USA in 2017 while it was 156% during the period of 2010-14 in India, primarily due to the late stage of the disease at diagnosis [3,4]. As there is no cure for relapsed ovarian cancer, the primary aim of treatment is to slow progression of the disease for as long as possible and improve or maintain the patient's quality of life.

Breast cancer has been ranked number one cancer among Indian females with age adjusted rate ranging from 4.4 to 41.0 per 100,000 women [2]. Mortality-to-incidence ratio was for breast cancer was found to be as high as 0.66 in rural registries whereas as low as 0.08 in urban registries [2]. It is projected that 56,276 and 1,79,790 Indian patients will be suffering from ovarian cancer and breast cancer respectively in 2020 [1]. In India, 5-year survival rate for patients with breast cancer is 661% during the period of 2010-14 [4]. Most of the Indian studies have showed an inverse relationship of stage-of disease with survival. Patients diagnosed with BRCA-related metastatic breast cancer are often younger than other breast cancer patients, and their disease is often much more aggressive and difficult to treat. While there is currently no cure for metastatic breast cancer, olaparib now offers a new, targeted option that may help to delay disease progression for these patients.

Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.1704.5 as compared to the previous close of Rs. 1683.6. The total number of shares traded during the day was 4256 in over 623 trades.

The stock hit an intraday high of Rs. 1740.9 and intraday low of 1662.5. The net turnover during the day was Rs. 7297931.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

Delta Magnets Ltd approves merger of Arrow Textiles Ltd and MMG

NBCC India Ltd secures business of Rs. 921.67 crore in August 2018

G E Shipping takes delivery of Secondhand Very Large Gas Carrier 'Jag Vasant'

RBI allows Rana Kapoor to continue as MD & CEO of YES Bank till Jan 31, 2019

Asian Paints Ltd announces sad demise of Shri Ashwin Choksi

CCI imposes penalty of Rs. 12.35 crore to Bajaj Hindusthan Sugar Ltd

Blue Coast Hotels Ltd hands over possession of Goa hotel to ITC

Shankara Building Products Limited opens its 134th Store

Allahabad Bank to raise Rs. 1500 crore through QIP in 2018-19

Manali Petrochemicals Ltd to commence supply of new products from Sep 19, 2018

HPL Electric Participates in 12th edition of 'Renewable Energy India Expo 2018'

Vaibhav Global Ltd allots 1666 shares

Kanpur Plastipack Ltd extends date for payment of final call money

Newgen Software Technologies Ltd signs agreement with HP for supply of software licences

Raghav Productivity Enhancers Ltd bestowed with Rajasthan Udyog Ratan Award 2018

Varroc Engineering arm forms JV with ELBA SA

Nucleus Software's lending software goes live at VietCredit Finance Joint-Stock Company

Glenmark Pharmaceuticals inducted into the DJSI Emerging Market 2018

HFCL bags purchase order worth Rs. 611 crore from BSNL

26 young people with type 1 diabetes successfully surmount 13,000 feet in 'India's 2nd T1D Challenge 2018'

TVS Motor Company strengthens its presence in Mexico

Brand Idea urges people for 'Responsible Use of Social Media' through the latest #MeriRealLife campaign

Bharti Foundation expands Quality Support Program to Karnataka

Ambuja Cement among the top 5 in global DJSI ranking-2018

Dish TV: D2H brand increases focus on South, launches new customer awareness TVC

Tata Steel Limited completes the acquisition of 51% equity stake in Creative Port Development Private Limited

Clariant Chemicals India Ltd updates on announcement from holding company

Lupin appoints Alok Sonig as CEO - US Generics and Global Head - Generics R&D & Biosimilars

KIOCL Ltd approves buyback of 1,25,88,235 equity shares at Rs. 170

IL&FS Transportation Networks Ltd arm gets claim from NHAI

Vyapar Industries Ltd approves sale of part investment in Beneficent Knowledge Parks & Properties Ltd

TI Financial Holdings Limited to change name

NIIT Technologies introduces Chain-m, a Blockchain powered solution for Airlines and its partners

Steel Strips Wheels Ltd announces resignation of CFO

RITES Ltd secures additional turnkey contract work for Rs. 436 crore

Sun Pharma announces receipt of European Commission approval for ILUMETRI® by Almirall

Tata iQ Selects TCS Jile™ to Drive Agile Transformation

ICICI Prudential Life and Saraswat Co-operative Bank sign bancassurance partnership

Woodpecker Distilleries & Breweries Private Ltd. launches Blackfort Lager Beer

DAC Approves Procurement of Equipment Worth Rs 9,100 Crores

ITI Limited Conferred with National Safety Awards

Future Market Networks Ltd completes acquisition of 50% in Future Retail Destination Ltd

Strides Pharma Science Ltd updates on USFDA inspection at Bangalore facility

Lime Chemicals Ltd appoints company secretary

Indian Hume Pipe Company Ltd receives LoA for Rs. 221.72 crore order

PNC Triveni Sangam Highways Pvt Ltd achieves financial closure

Financial Creditors initiate CIRP against Pratibha Industries Ltd

Bank of Baroda confirms intimation received on merger of Vijaya Bank and Dena Bank

L&T Construction Wins Orders Valued Rs. 2048 Crore

TVS NTORQ 125 crosses 1 lakh sales mark, launches new Metallic Red colour

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018